Page last updated: 2024-12-08

naphthalenediimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

naphthalenediimide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID157464
CHEMBL ID280910
SCHEMBL ID13000618
MeSH IDM0537522

Synonyms (25)

Synonym
naphthalene diimide
bdbm50196501
2,7-bis-(2-dimethylamino-ethyl)-benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone
2,7-bis-(2-dimethylamino-ethyl)-benzo[lmn][3,8]phenanthroline-1,3,6,8-etraone
CHEMBL280910 ,
benzo(lmn)(3,8)phenanthroline-1,3,6,8(2h,7h)-tetrone, 2,7-bis(2-(dimethylamino)ethyl)-
22291-04-9
naphthalenediimide
AKOS022174986
SCHEMBL13000618
2,7-bis(2-(dimethylamino)ethyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2h,7h)-tetraone
B4583
n,n'-bis[2-(dimethylamino)ethyl]-1,8:4,5-naphthalenetetracarboxdiimide
DTXSID80176838
mfcd27923061
2,7-bis[2-(dimethylamino)ethyl]benzo[lmn][3,8]phenanthroline-1,3,6,8(2h,7h)-tetrone
6,13-bis[2-(dimethylamino)ethyl]-6,13-diazatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),2,4(16),8,10-pentaene-5,7,12,14-tetrone
D89095
A919720
6,13-bis[2-(dimethylamino)ethyl]-6,13-diazatetracyclo[6.6.2.0^{4,16.0^{11,15]hexadeca-1(15),2,4(16),8,10-pentaene-5,7,12,14-tetrone
AS-57196
XAA29104
2,7-bis(2-(dimethylamino)ethyl)benzo[lmn][3,8]phenanthroline-
1,3,6,8(2h,7h)-tetraone
2,7-dis(2-(dimethylamino)ethyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2h,7h)-tetraone

Research Excerpts

Effects

ExcerptReferenceRelevance
"Naphthalenediimides (NDIs) have been extensively studied due to their tunable luminescent properties. "( Chiral Naphthalenediimides with High-Efficiency Fluorescence and Circularly Polarized Luminescence in the Solid State for the Application in Organic Optoelectronics.
Gao, L; Gao, Y; Jin, R; Kang, C; Ma, X; Wang, L, 2023
)
2.81

Dosage Studied

ExcerptRelevanceReference
" The lead compound induces cellular senescence but does not inhibit telomerase activity at the nanomolar dosage levels required for inhibition of cellular proliferation."( Structure-based design and evaluation of naphthalene diimide G-quadruplex ligands as telomere targeting agents in pancreatic cancer cells.
Collie, GW; Dale, AG; Gunaratnam, M; Micco, M; Neidle, S; Ohnmacht, SA; Pazitna, I; Reszka, AP, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase I, thermostableThermus aquaticusIC50 (µMol)1.50001.50001.50001.5000AID283978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID120545Compound was evaluated for inhibitory activity in vivo against P388 leukemia cells in mice at a dose of 3.12 mg/kg upon intraperitoneal administration1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
N-(Aminoalkyl)imide antineoplastic agents. Synthesis and biological activity.
AID640731Cytotoxicity against human Jurkat T cells assessed as decrease in cell viability after 24 hrs by flow cytometric analysis2012European journal of medicinal chemistry, Feb, Volume: 48Design, synthesis and biological evaluation of new naphtalene diimides bearing isothiocyanate functionality.
AID314486Stabilization of calf thymus duplex DNA at 0.5 uM by FRET assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Tri- and tetra-substituted naphthalene diimides as potent G-quadruplex ligands.
AID314491Antiproliferative activity against human A549 cells by SRB assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Tri- and tetra-substituted naphthalene diimides as potent G-quadruplex ligands.
AID120674Compound was evaluated for inhibitory activity in vivo against P388 leukemia cells in mice at a dose of 6.25 mg/kg upon intraperitoneal administration1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
N-(Aminoalkyl)imide antineoplastic agents. Synthesis and biological activity.
AID314492Antiproliferative activity against human WI38 cells by SRB assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Tri- and tetra-substituted naphthalene diimides as potent G-quadruplex ligands.
AID283978Inhibition of Taq polymerase2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Tri-, tetra- and heptacyclic perylene analogues as new potential antineoplastic agents based on DNA telomerase inhibition.
AID283982Cytotoxicity against human HT29 cells by MTT assay2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Tri-, tetra- and heptacyclic perylene analogues as new potential antineoplastic agents based on DNA telomerase inhibition.
AID314485Stabilization of human telomeric G4 DNA quadruplex at 0.5 uM by FRET assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Tri- and tetra-substituted naphthalene diimides as potent G-quadruplex ligands.
AID283983Inhibition of telomerase in JR8 cell extract at 0 to 40 uM by TRAP assay2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Tri-, tetra- and heptacyclic perylene analogues as new potential antineoplastic agents based on DNA telomerase inhibition.
AID314490Antiproliferative activity against human MCF7 cells by SRB assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Tri- and tetra-substituted naphthalene diimides as potent G-quadruplex ligands.
AID283981Cytotoxicity against human H460 cells by MTT assay2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Tri-, tetra- and heptacyclic perylene analogues as new potential antineoplastic agents based on DNA telomerase inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (229)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.44)18.7374
1990's4 (1.75)18.2507
2000's38 (16.59)29.6817
2010's145 (63.32)24.3611
2020's41 (17.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.77 (24.57)
Research Supply Index5.45 (2.92)
Research Growth Index5.79 (4.65)
Search Engine Demand Index47.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (1.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other227 (98.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]